ebola
viru
filament
rna
viru
belong
filovirida
famili
negativestrand
rna
genom
kb
contain
seven
gene
ebola
viru
zoonot
viru
mechan
maintain
natur
reservoir
fruit
bat
fulli
understood
first
ebola
outbreak
human
popul
happen
congo
sudan
ebola
outbreak
zair
ebolaviru
first
isol
character
sinc
five
speci
ebolaviru
identifi
zair
sudan
forest
bundibugyo
reston
ebolaviru
ebola
viru
highli
infecti
human
nonhuman
primat
caus
hemorrhag
fever
fatal
rate
recent
epidem
caus
nearli
human
infect
death
west
africa
far
fdaapprov
treatment
vaccin
ebola
viru
diseas
recombin
vesicular
stomat
viru
glycoprotein
rvsvgp
vaccin
shown
promis
protect
guinea
ring
vaccin
trial
although
much
attent
drawn
ebola
viru
research
sinc
direct
handl
ebola
viru
limit
biosafeti
level
laboratori
develop
safe
substitut
import
use
highthroughput
screen
therapeut
diagnost
screen
neutral
human
sera
understand
entri
mechan
ebola
viru
ebola
viru
lipidenvelop
viru
ebola
viru
glycoprotein
ebovgp
protein
present
viru
surfac
ebovgp
play
import
role
viru
cell
entri
key
target
neutral
antibodi
current
avail
viral
surrog
ebov
ebovgppseudotyp
lentiviru
vsv
expos
ebovgp
viral
surfac
howev
ebovgppseudotyp
virus
still
differ
wildtyp
ebola
viru
vari
biolog
properti
suscept
neutral
antibodi
recent
nation
institut
biolog
standard
control
compar
differ
ebola
virusbas
vitro
assay
wildtyp
ebola
viru
neutral
panel
antibodi
sera
result
show
variabl
gener
poor
correl
therefor
design
compar
addit
ebovgppseudotyp
virus
import
accur
determin
correl
protect
describ
new
ebola
viru
pseudotyp
esflu
base
nonrepl
influenza
viru
sflu
viru
influenza
viru
also
negativestrand
rna
viru
sflu
viru
hemagglutinin
ha
gene
replac
enhanc
green
fluoresc
protein
egfp
report
found
unlik
cell
line
cell
stabli
express
high
level
ebovgp
without
appar
toxic
pseudotyp
done
simpli
infect
produc
cell
line
stabli
transduc
express
ebovgp
seed
sflu
viru
express
ebovgp
produc
cell
line
complement
defect
ha
express
sflu
viru
replic
level
suffici
perform
drug
inhibit
antibodi
neutral
assay
without
concentr
stabl
produc
cell
line
allow
easi
product
esflu
viru
without
need
repeat
transfect
round
viru
product
comparison
lentiviru
pseudotyp
vsv
pseudotyp
method
esflu
viru
contain
genet
materi
ebola
viru
infect
cell
line
express
ebovgp
influenza
viru
ha
singl
cycl
therefor
handl
biosafeti
level
shown
esflu
viru
easi
produc
resembl
ebola
viru
cell
entri
process
also
compar
esflu
viru
recombin
wildtyp
ebola
viru
drug
screen
assay
result
highli
correl
esflu
viru
use
surrog
ebola
viru
vitro
studi
sflu
viru
pseudotyp
influenza
viru
endogen
ha
sequenc
remov
previous
pseudotyp
differ
subtyp
influenza
viru
ha
incorpor
ebovgp
sflu
viru
envelop
use
lentivir
vector
transduc
cell
express
fulllength
zair
strain
ebovgp
gene
zair
zair
transduc
cell
healthi
morpholog
fig
ebovgp
express
cell
surfac
detect
gpspecif
monoclon
antibodi
mab
cell
high
express
ebovgp
sort
store
esiat
cell
line
gp
surfac
express
toxic
cell
stabl
uniform
least
ninth
passag
fig
clone
seed
sflu
viru
coat
influenza
viru
ha
ad
propag
esiat
cell
produc
ebovgppseudotyp
sflu
viru
h
cultur
supernat
harvest
titrat
indic
cell
infect
infect
cell
express
egfp
encod
viru
name
new
pseudotyp
esflu
esflu
viru
reach
lower
titer
virus
grown
hatransduc
produc
cell
form
smaller
diffus
plaqu
viru
fig
typic
effect
concentr
dilut
esflu
viru
h
compar
viru
fig
dilut
number
cell
per
well
cell
infect
dose
ml
calcul
esflu
viru
batch
sflu
viru
batch
howev
harvest
cultur
supernat
esiat
cell
contain
adequ
pseudovirion
dilut
give
close
full
infect
cell
well
plate
purif
concentr
step
need
screen
inhibitori
drug
antibodi
protocol
also
abl
pseudotyp
sflu
viru
bundibugyo
sudan
mayingazair
ebovgp
similar
viral
titer
data
shown
shown
previous
transmembran
cytoplasm
domain
influenza
viru
ha
import
influenza
viral
particl
assembl
potenti
improv
viral
titer
esflu
viru
design
gpha
hybrid
protein
contain
extracellular
domain
ebovgp
transmembran
cytoplasm
domain
ha
transduct
sort
gpha
protein
detect
mab
surfac
ehsiat
cell
level
similar
esiat
cell
howev
surpris
infect
sflu
viru
detect
ehsiat
cell
supernat
data
shown
niemann
pick
protein
identifi
key
entri
receptor
ebola
viru
level
late
endosomelysosom
membran
infect
wildtyp
hela
cell
two
knockout
ko
hela
cell
line
esflu
virus
fig
wildtyp
hela
cell
infect
esflu
viru
express
egfp
esflu
viru
infect
cell
complet
block
contrast
percent
infect
viru
wildtyp
cell
show
esflu
viru
requir
cell
entri
resembl
wildtyp
ebola
viru
cell
entri
mechan
valid
new
ebovgppseudotyp
esflu
viru
test
antibodi
microneutr
mn
assay
comparison
control
pseudotyp
viru
ebovgpco
lentiviru
pseudotyp
gplenti
viru
contain
exactli
sflu
viru
core
esflu
viru
differ
surfac
glycoprotein
gplenti
lentiviru
pseudotyp
fulllength
zair
strain
ebovgp
match
esflu
viru
neutral
profil
two
antibodi
shown
fig
human
mab
specif
bind
zair
speci
ebovgp
recogn
conform
epitop
base
gp
neutral
esflu
viru
gplenti
pseudotyp
viru
similar
report
wildtyp
ebola
viru
ngml
neutral
viru
neutral
effect
confirm
fluoresc
microscopi
fig
f
contrast
mab
neutral
viru
neutral
esflu
viru
gplenti
pseudotyp
viru
show
esflu
viruspseudotyp
viru
produc
coat
correctli
fold
ebovgp
requir
molecul
infect
indic
cell
result
show
esflu
viru
use
screen
neutral
antibodi
ebola
viru
literatur
sever
drug
screen
studi
done
wildtyp
ebola
viru
ebola
viru
surrog
ebola
viruslik
particl
ebovgppseudotyp
recombin
vsv
lentiviru
shown
drug
molecul
divers
pharmacolog
function
inhibit
ebola
viru
infect
vitro
verifi
use
esflu
viru
drug
screen
assay
select
sever
type
drug
molecul
test
repeatedli
literatur
screen
esflu
viru
drug
inhibit
assay
tabl
summar
initi
inhibitor
test
esflu
viru
infect
effect
block
differ
group
drug
drug
concentr
egfp
fluoresc
reduc
rang
literatur
screen
tabl
repeat
least
three
time
calcul
geometr
mean
confid
interv
ci
also
screen
drug
viru
see
tabl
supplement
materi
inhibit
viru
except
niclosamid
figur
show
exampl
drug
inhibit
tetrandrin
infect
level
quantifi
measur
egfp
express
also
estim
toxic
drug
stain
cell
fluoresc
label
wheat
germ
agglutinin
wga
infect
fixat
wash
wga
lectin
bind
cell
surfac
nacetyldglucosamin
sialic
acid
cell
good
condit
remain
adher
plate
analysi
detect
wga
dead
unhealthi
cell
detach
wash
away
wga
stain
allow
quick
indic
drug
toxic
highthroughput
plate
screen
assay
verifi
light
microscopi
fig
calcul
logp
pka
valu
inhibitor
shown
tabl
found
other
mani
drug
molecul
inhibit
ebola
viru
high
logp
pka
valu
eg
amiodaron
verapamil
clomiphen
classifi
cation
amphiphil
drug
also
noncation
amphiphil
inhibit
ebola
viru
entri
nethylnisopropyl
amilorid
eipa
niclosamid
potenti
mode
action
molecul
see
fig
establish
infect
esflu
viru
depend
receptor
inhibit
specif
antibodi
establish
small
molecul
proceed
formal
drug
screen
screen
drug
molecul
librari
sigmaaldrich
drug
inhibit
assay
test
effect
esflu
viru
infect
librari
contain
pharmacolog
activ
small
molecul
differ
molecular
target
drug
screen
first
round
select
drug
titrat
drug
inhibit
assay
calcul
total
molecul
inhibit
esflu
viru
infect
level
reach
toxic
vitro
fig
see
tabl
inhibit
esflu
viru
comparison
molecul
inhibit
viru
molecul
tabl
also
inhibit
esflu
viru
thu
like
act
either
ebovgp
influenza
viru
ha
postentri
stage
independ
surfac
glycoprotein
see
molecul
inhibit
viru
inhibit
esflu
viru
detail
profil
inhibitor
shown
tabl
inhibitor
belong
varieti
pharmacolog
group
accord
descript
sigma
websit
fig
tabl
also
includ
small
molecul
test
addit
librari
give
total
esflu
viru
inhibitor
inhibit
esflu
virus
fig
tabl
screen
system
quantifi
infect
measur
overal
fluoresc
level
cell
fluoresc
microscop
clear
drug
reduc
number
fluoresc
cell
ie
reduc
proport
infect
cell
drug
concentr
increas
twelv
drug
howev
caus
reduc
overal
fluoresc
level
infect
cell
without
reduc
number
fluoresc
cell
significantli
drug
also
affect
viru
infect
suggest
act
postentri
phase
limit
express
viral
protein
tabl
annot
dimmer
drug
molecul
inhibit
esflu
virus
reduc
number
infect
cell
thu
may
affect
function
glycoprotein
molecul
inhibit
esflu
viru
plot
fig
includ
inhibitor
librari
addit
individu
drug
test
addit
librari
compar
screen
result
recent
report
johansen
et
al
use
wildtyp
ebov
screen
inhibitor
two
librari
drug
common
tabl
result
obtain
agre
inhibitor
effect
rest
drug
posit
screen
posit
screen
done
johansen
et
al
use
twotail
fisher
exact
test
statist
analysi
comparison
correl
signific
p
one
main
differ
two
screen
rang
drug
concentr
test
highest
concentr
test
screen
done
johansen
et
al
wherea
screen
drug
screen
concentr
toxic
reach
reason
great
major
agreement
occur
drug
assay
tabl
drug
posit
screen
select
ebastin
imipramin
verapamil
order
individu
sigma
confirm
inhibitori
effect
three
drug
inhibitori
effect
esflu
viru
compar
librari
screen
three
drug
previous
report
inhibitor
drug
posit
screen
done
johansen
et
al
neg
screen
order
individu
sigma
test
auranofin
sigma
code
bepridil
calcimycin
diphenyleneiodonium
doxylamin
linezolid
naproxen
nocodazol
perphenazin
rotenon
sanguinarin
serotonin
thapsigargin
bepridil
calcium
channel
inhibitor
perphenazin
cation
amphiphil
librari
inhibit
esflu
viru
individu
order
sampl
show
specif
inhibit
esflu
viru
bepridil
perphenazin
indic
variat
due
fals
neg
librari
prepar
sigma
doxylamin
disopyramid
linezolid
naproxen
rotenon
sanguinarin
confirm
noninhibitor
esflu
viru
assay
auranofin
calcimycin
diphenyleneiodonium
nocodazol
thapsigargin
toxic
cell
even
yet
cell
still
infect
none
drug
test
inhibit
viru
design
esflu
viru
base
pseudotyp
influenza
viru
sflu
viru
previous
develop
group
similar
singlecycl
influenza
viru
pseudotyp
esflu
viru
nonrepl
pseudotyp
viru
manipul
biosafeti
level
contain
genet
inform
ebola
viru
eas
product
found
cell
line
stabli
express
fulllength
ebovgp
without
toxic
although
replic
sflu
viru
core
ebovgptransduc
cell
line
order
magnitud
less
effici
haexpress
cell
fig
product
pseudotyp
scale
suffici
highthroughput
assay
simpl
effici
esflu
viru
encod
egfp
report
prefer
firefli
luciferas
betagalactosidas
enzym
report
much
sensit
egfp
lowlevel
infect
amplifi
detect
howev
cell
lyse
releas
enzym
substrat
ad
oneround
readout
comparison
drug
inhibit
neutral
assay
sflu
viru
ad
indic
cell
multipl
infect
moi
produc
bright
egfp
fluoresc
cell
stabl
month
fixat
measur
plate
reader
observ
microscop
without
manipul
fig
valid
esflu
viru
use
surrog
ebola
viru
show
infect
fulli
depend
receptor
fig
inhibit
ebovgpspecif
mab
fig
also
inhibit
wellcharacter
set
drug
thought
act
variou
point
viral
entri
tabl
fig
sever
laboratori
observ
wide
varieti
fdaapprov
drug
inhibit
infect
cell
line
vitro
ebola
viru
screen
drug
librari
identifi
pharmacolog
activ
small
molecul
inhibit
esflu
viru
cell
entri
viru
test
parallel
esflu
viru
differenti
inhibit
specif
ebovgp
sflu
viru
core
identifi
molecul
librari
inhibit
esflu
viru
wherea
inhibit
viru
also
inhibit
esflu
viru
therefor
inhibitori
effect
drug
ebovgp
depend
compar
screen
result
list
drug
screen
johansen
et
al
screen
small
molecul
gfpexpress
ebola
viru
total
small
molecul
common
two
librari
johansen
et
al
versu
molecul
concord
result
two
screen
correl
statist
signific
p
noteworthi
identifi
least
calcium
channel
inhibitor
specif
inhibitor
esflu
viru
infect
independ
evid
exist
possibl
role
calcium
channel
lysosom
membran
viral
entri
perhap
effect
vesicl
fusion
recent
studi
suggest
twopor
channel
lysosom
calcium
channel
involv
ebola
viru
entri
process
could
target
calcium
channel
inhibitor
larg
group
inhibitor
share
cation
amphiphil
featur
ie
hydrophil
end
usual
weak
base
amin
group
high
pka
hydrophob
end
high
logp
therefor
like
concentr
lysosom
mechan
drug
inhibit
ebola
viru
entri
resolv
cation
amphiphil
drug
caus
increas
cholesterol
accumul
endosom
lysosom
ebovgp
membran
fusion
occur
other
influenc
lysosom
membran
stabil
indirectli
inhibit
acid
sphingomyelinas
also
known
function
inhibitor
acid
sphingomyelinas
may
indirect
effect
calcium
mobil
lysosom
accumul
sphingosin
addit
power
member
cation
amphiphil
group
toremifen
shown
bind
hydrophob
pocket
ebovgp
destabil
molecul
vitro
may
two
site
action
mani
drug
found
risk
caus
longqt
syndrom
amiodaron
toremifen
clarithromycin
inhibit
potassium
channel
herg
human
etheragogo
cardiac
myocyt
commonli
associ
longqt
syndrom
compar
drug
inhibit
esflu
viru
studi
herg
screen
literatur
identifi
least
indic
tabl
confirm
inhibitor
herg
channel
henc
may
danger
side
effect
cardiac
conduct
herg
binder
typic
cation
amphiphil
drug
unclear
whether
featur
inhibit
ebola
viru
entri
also
predispos
effect
herg
bind
lengthen
qt
interv
dissect
mechan
action
therefor
necessari
administ
ebola
virusinfect
patient
although
fdaapprov
drug
potenti
mechan
action
drug
uncov
test
combin
act
differ
site
synergist
effect
may
valuabl
reduc
risk
one
advantag
sflu
viru
pseudotyp
infect
cell
express
egfp
fluoresc
brightli
visual
inspect
cell
assay
plate
fluoresc
microscopi
reveal
two
form
inhibit
could
distinguish
case
drug
reduc
number
infect
cell
drug
act
ebovgpdepend
manner
reduc
number
infect
cell
consist
inhibit
viral
entri
tabl
contrast
case
drug
reduc
number
infect
cell
reduc
intens
fluoresc
express
infect
cell
popul
drug
test
reduc
fluoresc
intens
tabl
also
inhibit
viru
gener
agent
similar
esflu
virus
consist
act
function
control
influenza
viru
core
common
suggest
affect
viru
postentri
level
like
faviparivir
specif
inhibitor
rnadepend
rna
polymeras
initi
synthes
inhibit
influenza
viru
later
found
effect
ebola
viru
vitro
addit
aminopterin
dihydrofol
reductas
inhibitor
brequinar
dihydroorot
dehydrogenas
inhibitor
ribavirin
guanosin
analogu
nucleosid
inhibitor
may
affect
transcript
indirectli
block
biosynthesi
nucleotid
interest
spiranalacton
triamteren
dimmer
effect
drug
use
clinic
diuret
block
sodium
channel
unclear
affect
function
influenza
viru
core
postentri
level
drug
inhibit
esflu
virus
reduc
number
infect
cell
thu
may
inhibit
cell
entri
ha
ebovgp
chloroquin
lysosomotrop
drug
niclosamid
may
act
reduc
lysosom
proton
concentr
influenc
effici
cathepsin
endosomedigest
ebovgp
niclosamid
proton
ionophor
similar
viru
esflu
viru
entri
arbidol
may
inhibit
fusion
viral
lysosom
membran
manner
relat
effect
influenza
viru
ha
although
find
inhibit
arbidol
sflu
viru
sinc
confirm
inhibit
sflu
viru
coat
well
data
shown
recent
structur
reveal
arbidol
bound
ha
influenza
viru
may
interest
analyz
bind
arbidol
ebovgp
summari
develop
new
surrog
esflu
viru
ebola
viru
mimic
ebola
viru
level
cell
entri
valuabl
tool
screen
antibodi
therapeut
drug
well
studi
fundament
biolog
ebola
viru
entri
process
cdna
encod
ebovgp
zair
ebolaviru
makona
genbank
access
human
codon
optim
synthes
geneart
lentivir
vector
phrsin
engin
incorpor
ebovgp
cdna
transduc
madindarbi
canin
kidney
epitheli
cell
lentiviru
express
fulllength
ebovgp
transduc
cell
stain
ebovgpspecif
mab
specif
zair
crossreact
ebola
viru
speci
p
rijal
unpublish
data
second
layer
fluorescein
isothiocyan
fitc
conjug
goat
antihuman
antibodi
life
technolog
refer
stain
cell
bulk
sort
fluorescenceactiv
cell
sorter
fac
achiev
maxim
express
ebovgp
esiat
cell
line
shown
fig
ebovgp
detect
sort
cell
stabl
uniform
least
ninth
passag
sort
esflu
viru
gener
basi
nonrepl
pseudotyp
influenza
viru
sflu
previous
describ
use
version
express
enhanc
green
fluoresc
protein
segfp
sha
code
sequenc
replac
egfp
report
gene
isol
subclon
origin
sflu
viru
show
brighter
fluoresc
found
singl
mutat
ha
signal
sequenc
ncbi
refer
sequenc
access
abrog
outoffram
atg
interf
downstream
egfp
express
subsequ
version
sflu
viru
contain
enhanc
give
suffici
bright
fluoresc
signal
infect
cell
read
clariostar
fluoresc
plate
reader
seed
virus
doubli
clone
limit
dilut
seed
esiat
produc
cell
seed
sflu
virus
coat
ha
titrat
standard
tissu
cultur
infect
dose
assay
cell
fluoresc
detect
describ
titrat
experi
reveal
rel
high
moi
approxim
seed
sflu
viru
per
cell
ad
infect
esiat
cell
produc
highest
titer
esflu
viru
wherea
lower
moi
adequ
seed
hasiat
cell
line
viral
growth
medium
vgm
use
dulbecco
modifi
eagl
medium
dmem
bovin
serum
albumin
mm
hepe
mm
glutamin
uml
penicillin
streptomycin
h
incub
esiat
cell
seed
sflu
viru
remain
seed
viru
remov
wash
phosphatebuff
salin
pb
cell
incub
vgm
h
incub
without
ad
trypsin
cultur
supernat
harvest
store
aliquot
replic
hapseudotyp
virus
requir
addit
trypsin
describ
previous
seed
sflu
virus
coat
influenza
viru
ha
titrat
concentr
replicationcompet
clone
standard
limitingdilut
method
describ
powel
et
al
well
contain
clone
egfpexpress
sflu
viru
standard
deviat
control
well
detect
plate
reader
describ
calcul
reedmuench
method
batch
esflu
virus
titrat
infect
indic
cell
overnight
infect
harvest
cultur
supernat
contain
esflu
sflu
viru
titrat
dilut
vgm
across
flatbottom
plate
fig
indic
cell
wash
pb
cell
vgm
ad
well
incub
h
medium
remov
well
cell
fix
formalin
pb
min
viru
titer
assess
egfp
fluoresc
analyz
plate
reader
clariostar
dilut
viru
give
maximum
plateau
fluoresc
signal
calcul
linear
interpol
dilut
obtain
best
fit
titrat
curv
poisson
distribut
similar
data
shown
typic
dilut
esflu
viru
harvest
h
compar
viru
fig
dilut
number
cell
per
well
calcul
esflu
viru
batch
sflu
viru
batch
inhibit
assay
esflu
virus
use
concentr
gave
closetomaximum
plateau
fluoresc
infect
cell
moi
valu
use
normal
fluoresc
readout
percentag
maximum
figur
fig
b
studi
evalu
screen
done
zair
esflu
virus
parallel
fluoresc
plate
readout
perform
costar
cell
cultur
plate
costar
chose
costar
micropl
mode
clariostar
softwar
measur
egfp
level
fluoresc
excit
nm
bandwidth
nm
emiss
nm
bandwidth
nm
dichroic
filter
well
flash
diamet
fluoresc
readout
top
optic
give
orbit
averag
valu
measur
wga
alexa
fluor
conjug
drug
inhibit
assay
fluoresc
excit
nm
bandwidth
nm
emiss
nm
bandwidth
nm
well
flash
mm
fluoresc
readout
top
optic
give
orbit
averag
valu
focal
length
gain
adjust
plate
read
gener
optim
focal
length
mm
gain
egfp
channel
adjust
gain
adjust
protein
key
receptor
ebola
viru
cell
entri
level
lysosom
membran
two
ko
hela
cell
line
name
exon
delet
gener
techniqu
gener
verif
ko
cell
line
describ
previous
tharkeshwar
et
al
total
wildtyp
hela
cell
seed
tissu
cultur
plate
medium
dmem
fetal
calf
serum
mm
glutamin
uml
penicillin
streptomycin
night
infect
infect
medium
remov
cell
wash
pb
cell
infect
maxim
dose
esflu
viru
moi
viru
moi
incub
overnight
infect
cell
trypsin
transfer
polypropylen
tube
percent
infect
analyz
count
fluoresc
cell
flow
cytomet
cyan
adp
analyz
mn
assay
use
measur
inhibit
titer
antibodi
viru
entri
vitro
assay
done
describ
powel
et
al
minor
modif
esflu
moi
moi
virus
dilut
vgm
give
plateau
express
egfp
cell
overnight
infect
flatbottom
plate
volum
viru
preincub
antibodi
dilut
h
total
cell
vgm
seed
well
overnight
infect
allow
infect
medium
remov
well
cell
fix
formalin
pb
min
formalin
replac
pb
plate
analyz
fluoresc
plate
reader
clariostar
fluoresc
microscopi
calcul
linear
interpol
human
mab
specif
bind
zair
ebovgp
neutral
wildtyp
ebov
vitro
version
reconstitut
sequenc
publish
crystal
structur
pdb
file
pdb
code
human
mab
made
inhous
specif
bind
ha
neutral
viru
ebovgppseudotyp
lentiviru
gplenti
use
studi
coat
ebovgp
zair
esflu
viru
gplenti
carri
firefli
luciferas
report
gene
fiftymicrolit
volum
gplenti
pseudotyp
viru
preincub
antibodi
dilut
h
cell
ad
cell
incub
viru
infect
vgm
h
h
infect
quantifi
measur
luciferas
report
express
medium
remov
well
cell
lyse
glolysi
buffer
promega
min
brightglo
promega
substrat
ad
enzymat
reaction
solut
transfer
opaqu
plate
luminesc
measur
glomaxmulti
detect
system
promega
small
inhibitor
molecul
includ
librari
use
studi
order
sigmaaldrich
store
mm
dimethyl
sulfoxid
except
order
merck
catalog
provid
collabor
antoni
galion
drug
dilut
vgm
give
start
concentr
unless
state
otherwis
titrat
vgm
dilut
across
plate
total
cell
seed
vgm
preincub
drug
h
volum
esflu
moi
moi
viru
dilut
vgm
give
plateau
express
egfp
cell
ad
overnight
infect
cell
fix
formalin
pb
min
formalin
replac
pb
plate
analyz
fluoresc
plate
reader
clariostar
mn
assay
infect
inhibit
quantifi
measur
egfp
express
level
three
measur
made
drug
ci
calcul
tabl
toxic
effect
cell
mani
drug
molecul
high
concentr
dead
cell
wash
away
plate
read
may
give
fals
low
egfp
fluoresc
read
plate
reader
detect
visual
inspect
fluoresc
microscop
estim
number
cell
remain
well
plate
stain
wga
cell
fix
wash
pb
wga
lectin
bind
sialic
acid
nacetylglucosaminyl
residu
cell
surfac
volum
wga
alexa
fluor
conjug
thermofish
catalog
ad
well
incub
room
temperatur
min
plate
wash
twice
pb
read
see
plate
reader
set
mention
johansen
et
al
screen
compound
antivir
activ
genet
engin
ebola
viru
express
egfp
egfpebov
vitro
tabl
list
experiment
data
small
molecul
screen
studi
molecul
test
also
found
sigma
librari
screen
esflu
viru
studi
compar
inhibitori
effect
compound
screen
ie
molecul
either
posit
inhibit
infect
neg
inhibit
infect
concentr
rang
test
perform
fisher
exact
test
measur
signific
associ
drug
molecul
list
tabl
logp
partit
paramet
pka
valu
strongest
basic
pka
estim
basi
chemic
structur
use
marvinsketch
program
